-

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2026 before the market opens on Thursday, April 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations.

The call will be webcast live on the “Investors” section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 470-1428 within the U.S. or +1 (646) 844-6383 outside the U.S. The access code is 723173.

The earnings press release and related information can also be found in that section of our website, under the heading “Financials”. A replay of the call will be available under “News, Events & Presentations” through Wednesday, July 22, 2026.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability. Global pipelines for protein therapeutics, including complex biologics and biosimilars used to treat conditions ranging from cancer to autoimmune and rare diseases, continue to expand. This...

Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before. The Thermo Scientific™ Glacios™ 3 Cryo-TEM offers researchers the next major advancement in 200 kV imaging and structural analysis. Cryogenic electron microscopy (cryo-EM), an...

Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions

RIDGEFIELD, N.J.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery systems, alongside an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site. Together, these investments establish a fully integrated U.S.-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device c...
Back to Newsroom